- Marketing Authorization Application (MAA) based on data from the head-to-head OPTIMUM Phase 3 study, presented at the 35th Congress of The European Committee for Treatment and Research in Multiple Sclerosis
- Idorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, have a revenue-sharing agreement in respect to ponesimod
ALLSCHWIL, Switzerland I March 4, 2020 I Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a MAA to the European Medicines Agency (EMA) seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis (MS).
For further details please read the full announcement available here:
https://johnsonandjohnson.gcs-web.com/static-files/8444902a-4913-4258-bb4c-7d60f9db257f
About the Revenue Sharing Agreement
Idorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into the revenue-sharing agreement in respect to ponesimod. Under the terms of the revenue-sharing agreement, Idorsia Pharmaceuticals Ltd is entitled to receive quarterly payments of 8% of the net sales of ponesimod products from Actelion Pharmaceuticals Ltd.
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.
Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet – the ideal constellation to bringing R&D efforts to business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 800 highly qualified specialists dedicated to realizing our ambitious targets.
SOURCE: Idorsia
Post Views: 28
- Marketing Authorization Application (MAA) based on data from the head-to-head OPTIMUM Phase 3 study, presented at the 35th Congress of The European Committee for Treatment and Research in Multiple Sclerosis
- Idorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, have a revenue-sharing agreement in respect to ponesimod
ALLSCHWIL, Switzerland I March 4, 2020 I Idorsia Ltd (SIX: IDIA) today informed that the Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a MAA to the European Medicines Agency (EMA) seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis (MS).
For further details please read the full announcement available here:
https://johnsonandjohnson.gcs-web.com/static-files/8444902a-4913-4258-bb4c-7d60f9db257f
About the Revenue Sharing Agreement
Idorsia Pharmaceuticals Ltd and Actelion Pharmaceuticals Ltd, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, have entered into the revenue-sharing agreement in respect to ponesimod. Under the terms of the revenue-sharing agreement, Idorsia Pharmaceuticals Ltd is entitled to receive quarterly payments of 8% of the net sales of ponesimod products from Actelion Pharmaceuticals Ltd.
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.
Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet – the ideal constellation to bringing R&D efforts to business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 800 highly qualified specialists dedicated to realizing our ambitious targets.
SOURCE: Idorsia
Post Views: 28
